Basilea files antifungal in the EU
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica has filed its novel broad-spectrum antifungal isavuconazole in the EU for use in invasive aspergillosis and mucormycosis (zygomycosis) in adults; the application has been accepted for review.